Schering takes Resovist to Japan:
This article was originally published in Clinica
Executive Summary
Schering has received Japanese market approval for its liver-specific MRI contrast media, Resovist. The product will be marketed by the firm's Japanese subsidiary, Nihon Schering KK. Resovist, which was approved in Europe in 2001, will be available in around ten countries by the end of the year, said Schering. It is used for the detection and characterisation of especially small focal liver lesions, enabling doctors to make a reliable diagnosis at a very early stage, the company added.
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.